Katherine A. High's most recent trade in Incyte Corp. was a trade of 9,216 Non Qualfied Stock Option (right to buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 9,216 | 9,216 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 2,518 | 13,341 (0%) | 0% | 0 | Common Stock | |
| CRISPR Therapeutics AG | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 12,517 | 12,517 | - | - | Non Qualfied Stock Option (right to buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,830 | 10,823 (0%) | 0% | 0 | Common Stock | |
| CRISPR Therapeutics AG | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,294 | 11,294 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,505 | 7,993 (0%) | 0% | 0 | Common Stock | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,124 | 9,124 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,144 | 5,488 (0%) | 0% | 0 | Common Stock | |
| CRISPR Therapeutics AG | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 8,010 | 8,010 | - | - | Non-Qualified Stock Option (right to buy) | |
| Incyte | Katherine A. High | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 1,923 | 3,344 (0%) | 0% | 0 | Common Stock |